

# Cyclosporine Sparing with Mycophenolate Mofetil, Dac Renal Allograft Recipients: The CAESAR Study

American Journal of Transplantation

7, 560-570

DOI: [10.1111/j.1600-6143.2006.01645.x](https://doi.org/10.1111/j.1600-6143.2006.01645.x)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Daclizumab. Expert Opinion on Biological Therapy, 2007, 7, 1583-1596.	1.4	30
3	KIDNEY TRANSPLANTATION: CURRENT ISSUES AND FUTURE PROSPECTS. Acta Clinica Belgica, 2007, 62, 208-217.	0.5	4
4	Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation. New England Journal of Medicine, 2007, 357, 2562-2575.	13.9	1,603
5	New trends in immunosuppression for pediatric renal transplant recipients. Current Opinion in Organ Transplantation, 2007, 12, 509-514.	0.8	0
6	Minimization of calcineurin inhibitors: a review of de-novo strategies and conversion algorithms. Current Opinion in Organ Transplantation, 2007, 12, 624-635.	0.8	5
8	Clinical update: immunosuppression minimisation. Lancet, The, 2007, 369, 1676-1678.	6.3	31
9	Daclizumab prevents acute renal allograft rejection: 1 year analysis. Journal of Nanjing Medical University, 2007, 21, 257-261.	0.1	0
10	Immunosuppressive Strategies to Improve Outcomes of Kidney Transplantation. Seminars in Nephrology, 2007, 27, 377-392.	0.6	20
11	Can mTOR inhibitors reduce the risk of late kidney allograft failure?. Transplant International, 2007, 21, 070717083500001-???	0.8	14
12	Calcineurin inhibitor-free immunosuppression in kidney transplantation. Transplant International, 2007, 20, 813-827.	0.8	45
13	Lessons from the CAESAR Study: Calcineurin Inhibitors?Can't Live with Them and Can't Live without Them. American Journal of Transplantation, 2007, 7, 495-496.	2.6	6
14	Tacrolimus Exposure and Evolution of Renal Allograft Histology in the First Year After Transplantation. American Journal of Transplantation, 2007, 7, 2114-2123.	2.6	82
15	Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation. American Journal of Transplantation, 2007, 7, 2496-2503.	2.6	368
16	Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991â€“2005. Nephrology, 2008, 13, 171-176.	0.7	17
17	Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transplant International, 2008, 21, 879-891.	0.8	100
18	Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient â€“ Case report and review of the literature. Pediatric Transplantation, 2008, 12, 914-917.	0.5	21
19	New immunosuppressive strategies and the risk of infection. Transplant Infectious Disease, 2008, 10, 379-384.	0.7	35
20	Prevention of diabetes: effect of mycophenolate mofetil and anti-CD25 on onset of diabetes in the DRBB rat. Pediatric Diabetes, 2008, 9, 596-601.	1.2	20

#	ARTICLE	IF	CITATIONS
21	Reducing Exposure to Calcineurin Inhibitors After Kidney Transplantation. American Journal of Kidney Diseases, 2008, 51, 882-884.	2.1	1
22	Calcineurin Inhibitor Withdrawal After Renal Transplantation with Alemtuzumab: Clinical Outcomes and Effect on T-Regulatory Cells. American Journal of Transplantation, 2008, 8, 1529-1536.	2.6	69
23	Minimization of calcineurin inhibitors to improve long-term outcomes in kidney transplantation. Transplant Immunology, 2008, 20, 21-28.	0.6	32
24	Maintenance immunosuppressive therapy in adult renal transplantation: A single center analysis. Transplant Immunology, 2008, 20, 14-20.	0.6	6
27	Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Yearbook of Urology, 2008, 2008, 31-32.	0.1	0
28	The Practical Utility of an Economic Analysis of Calcineurin Withdrawal following Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2008, 19, 1627-1628.	3.0	0
29	Prostate cancer in renal transplant recipients. Nephrology Dialysis Transplantation, 2008, 23, 2374-2380.	0.4	64
30	Minimizing Immunosuppression, an Alternative Approach to Reducing Side Effects. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, S101-S116.	2.2	118
31	Aggressive Immunosuppression Minimization Reduces Graft Loss Following Diagnosis of BK Virus-Associated Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1812-1819.	2.2	68
32	CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A. Nephrology Dialysis Transplantation, 2008, 23, 2024-2032.	0.4	52
33	Calcineurin Inhibitor Sparing in Renal Transplantation. Transplantation, 2008, 86, 761-767.	0.5	35
34	Renal Ischemia: Does Sex Matter?. Anesthesia and Analgesia, 2008, 107, 239-249.	1.1	92
35	Rationale and criteria of eligibility for calcineurin inhibitor interruption following kidney transplantation. Current Opinion in Organ Transplantation, 2008, 13, 609-613.	0.8	8
36	Recovery of Graft Function in Pediatric Kidney Transplantation Is Not Affected by Delayed Introduction of Cyclosporine. Transplantation, 2008, 86, 1199-1205.	0.5	3
37	Mycophenolic acid formulations in adult renal transplantation &ndash; update on efficacy and tolerability. Therapeutics and Clinical Risk Management, 2009, 5, 341.	0.9	11
38	Anti-interleukin-2 receptor antibodies&mdash;basiliximab and daclizumab&mdash;for the prevention of acute rejection in renal transplantation. Biologics: Targets and Therapy, 0, , 319.	3.0	1
39	Clinical utility of therapeutic drug monitoring of mycophenolic acid in transplantation medicine: Where are we? / Der klinische Nutzen des Therapeutischen Drug Monitoring von MycophenolsÄure in der Transplantationsmedizin: Wo stehen wir?. Laboratoriums Medizin, 2009, 33, 88-98.	0.1	1
40	Chronic Calcineurin Inhibitor Nephrotoxicity. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 2029-2034.	2.2	110

#	ARTICLE	IF	CITATIONS
41	Evolving trends in induction therapy. <i>Transplantation Reviews</i> , 2009, 23, 94-102.	1.2	6
42	Recent Developments in Kidney Transplantation-A Critical Assessment. <i>American Journal of Transplantation</i> , 2009, 9, 1265-1271.	2.6	62
43	Mycophenolate Blood Level Monitoring: Recent Progress. <i>American Journal of Transplantation</i> , 2009, 9, 1495-1499.	2.6	56
44	Calcineurin-Inhibitor-Free Immunosuppression Based on the JAK Inhibitor CP-690,550: A Pilot Study in De Novo Kidney Allograft Recipients. <i>American Journal of Transplantation</i> , 2009, 9, 1936-1945.	2.6	150
45	Calcineurin Inhibitor Minimization in the Symphony Study: Observational Results 3 Years after Transplantation. <i>American Journal of Transplantation</i> , 2009, 9, 1876-1885.	2.6	296
46	Mycophenolate Mofetil and Calcineurin-Inhibitor Reduction: Recent Progress. <i>American Journal of Transplantation</i> , 2009, 9, 2447-2452.	2.6	33
48	Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. <i>Liver Transplantation</i> , 2009, 15, S1-S34.	1.3	135
50	Calcineurin inhibitor minimization, withdrawal and avoidance protocols after kidney transplantation. <i>Transplant International</i> , 2009, 22, 69-77.	0.8	18
51	Minimization of immunosuppression after lung transplantation: current trends. <i>Transplant International</i> , 2009, 22, 90-95.	0.8	9
52	Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients. <i>Clinical Transplantation</i> , 2009, 23, 351-360.	0.8	18
53	Extended daclizumab monotherapy for rejection-free survival in non-adherent adolescent recipients of renal allografts. <i>Pediatric Transplantation</i> , 2009, 13, 927-932.	0.5	5
54	Management of Chronic Allograft Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 860-865.	2.2	43
55	Clinical Application of <i>Cordyceps sinensis</i> on Immunosuppressive Therapy in Renal Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 1565-1569.	0.3	32
56	Can Protocol Biopsy Better Inform Our Choices in Renal Transplantation?. <i>Transplantation Proceedings</i> , 2009, 41, S6-S8.	0.3	27
57	Conversion From Calcineurin Inhibitors to Sirolimus in Kidney Transplant Recipients: A Retrospective Cohort Study. <i>Transplantation Proceedings</i> , 2009, 41, 3308-3310.	0.3	5
58	Mycophenolic Acid Exposure after Administration of Mycophenolate Mofetil in the Presence and Absence of Cyclosporin in Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2009, 48, 329-341.	1.6	40
59	Immunosuppressive Drugs in Kidney Transplantation. <i>Drugs</i> , 2009, 69, 2227-2243.	4.9	267
60	Kidney Transplantation: The Ideal Immunosuppression Regimen. <i>Advances in Chronic Kidney Disease</i> , 2009, 16, 226-233.	0.6	31

#	ARTICLE	IF	CITATIONS
61	Treatment Strategies to Minimize or Prevent Chronic Allograft Dysfunction in Pediatric Renal Transplant Recipients. <i>Paediatric Drugs</i> , 2009, 11, 381-396.	1.3	31
62	Immunotherapy in Elderly Transplant Recipients. <i>Drugs and Aging</i> , 2009, 26, 715-737.	1.3	68
64	Calcineurin Inhibitor Nephrotoxicity. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 481-508.	2.2	1,178
65	Diagnostic value of T-cell monitoring assays in kidney transplantation. <i>Current Opinion in Organ Transplantation</i> , 2009, 14, 426-431.	0.8	24
66	Calcineurin Inhibitor Sparing With Mycophenolate in Kidney Transplantation: A Systematic Review and Meta-Analysis. <i>Transplantation</i> , 2009, 87, 591-605.	0.5	75
67	New Immunosuppressive Protocols With the Advent of Novel Biological Drugs. <i>Transplantation</i> , 2009, 88, S20-S23.	0.5	13
68	New Insights Into the Pharmacokinetics and Pharmacodynamics of the Calcineurin Inhibitors and Mycophenolic Acid: Possible Consequences for Therapeutic Drug Monitoring in Solid Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 416-435.	1.0	146
69	Everolimus With Very Low-Exposure Cyclosporine A in De Novo Kidney Transplantation: A Multicenter, Randomized, Controlled Trial. <i>Transplantation</i> , 2009, 88, 1194-1202.	0.5	90
70	CNI Sparing: Short-Term Results Promising, but Long-Term Data Needed. <i>Nephrology Times</i> , 2009, 2, 6-10.	0.0	0
71	Decreased Acute Rejection and Improved Renal Allograft Survival Using Sirolimus and Low-Dose Calcineurin Inhibitors without Induction Therapy. <i>International Journal of Artificial Organs</i> , 2009, 32, 371-380.	0.7	22
72	Minimization of Maintenance Immunosuppression Early After Renal Transplantation: An Interim Analysis. <i>Transplantation</i> , 2009, 88, 421-428.	0.5	57
73	Progress in Transplantation. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 246-249.	1.0	10
74	What can we learn from the transcriptional characterization of spontaneously tolerant transplant recipients?. <i>Current Opinion in Organ Transplantation</i> , 2010, 15, 435-440.	0.8	3
75	Maintenance Immunosuppressive Agents as Risk Factors for BK Virus Nephropathy: The Need for True Drug Exposure Measurements. <i>Transplantation</i> , 2010, 89, 1296-1297.	0.5	6
76	The Impact of IL2ra Induction Therapy in Kidney Transplantation Using Tacrolimus- and Mycophenolate-Based Immunosuppression. <i>Transplantation</i> , 2010, 90, 639-644.	0.5	35
77	Interleukin 2 receptor antagonists for kidney transplant recipients. <i>The Cochrane Library</i> , 2014, 2014, CD003897.	1.5	121
78	Long-Term Outcome of Living Related Renal Transplantation in a Patient with Short Bowel Syndrome. <i>Tohoku Journal of Experimental Medicine</i> , 2010, 221, 113-118.	0.5	7
79	Towards graft-specific immune suppression: Gene therapy of the transplanted kidney. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 1358-1368.	6.6	10

#	ARTICLE	IF	CITATIONS
81	Use of Kidney Function End Points in Kidney Transplant Trials: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2010, 56, 1140-1157.	2.1	23
82	Measuring vs estimating glomerular filtration rate in kidney transplantation. <i>Transplantation Reviews</i> , 2010, 24, 18-27.	1.2	21
83	Hypertension in the kidney transplant recipient. <i>Transplantation Reviews</i> , 2010, 24, 105-120.	1.2	48
84	Renal Transplantation in HIV-Infected Patients: The Paris Experience. <i>American Journal of Transplantation</i> , 2010, 10, 2263-2269.	2.6	79
85	Subclinical toxicity of calcineurin inhibitors in repeated protocol biopsies: an independent risk factor for chronic kidney allograft damage. <i>Transplant International</i> , 2010, 23, 364-373.	0.8	14
86	mTOR inhibition: the learning curve in kidney transplantation. <i>Transplant International</i> , 2010, 23, 447-460.	0.8	28
87	Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. <i>Transplant International</i> , 2010, 23, 1191-1204.	0.8	98
88	Acute rejection in low-toxicity regimens: clinical impact and risk factors in the Symphony study. <i>Clinical Transplantation</i> , 2010, 24, 500-509.	0.8	19
89	Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENCE Study 3-Year Follow Up. <i>Journal of Transplantation</i> , 2010, 2010, 1-11.	0.3	9
90	Immunosuppressive Therapies in Solid Organ Transplantation. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2010, 10, 21-30.	0.5	0
92	Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2004-2010.	0.4	93
93	Finding the right time for weaning off immunosuppression in solid organ transplant recipients. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 879-892.	1.3	24
94	A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3096-3106.	0.4	22
95	Deciphering calcineurin inhibitor nephrotoxicity: a pharmacological approach. <i>Pharmacogenomics</i> , 2010, 11, 1491-1501.	0.6	13
96	Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 283-292.	0.4	7
97	Antibody immunosuppressive therapy in solid-organ transplant. <i>MAbs</i> , 2010, 2, 148-156.	2.6	50
98	Potential of emerging immunosuppressive strategies to improve the posttransplant cardiovascular risk profile. <i>Kidney International</i> , 2010, 78, S15-S21.	2.6	6
99	Optimal immunosuppression to prevent chronic allograft dysfunction. <i>Kidney International</i> , 2010, 78, S66-S70.	2.6	20

#	ARTICLE	IF	CITATIONS
100	Alternatives to calcineurin inhibition in renal transplantation: belatacept, the first co-stimulation blocker. <i>Immunotherapy</i> , 2010, 2, 625-636.	1.0	24
101	Drug-Induced Seizures in Critically Ill Patients. , 2010, , 307-340.		0
102	Co-Stimulation Blockade as a New Strategy in Kidney Transplantation. <i>Drugs</i> , 2010, 70, 2121-2131.	4.9	32
103	Cyclosporine A suppresses keratinocyte cell death through MPTP inhibition in a model for skin cancer in organ transplant recipients. <i>Mitochondrion</i> , 2010, 10, 94-101.	1.6	73
104	Extended-Release Tacrolimus Therapy in De Novo Kidney Transplant Recipients: Single-Center Experience. <i>Transplantation Proceedings</i> , 2010, 42, 3034-3037.	0.3	16
105	Calcineurin Inhibitors in Renal Transplantation Still Needed but in Reduced Doses: A Review. <i>Transplantation Proceedings</i> , 2010, 42, 2205-2208.	0.3	23
106	Calcineurin Inhibitor-Free Immunosuppression in Pediatric Renal Transplantation. <i>Paediatric Drugs</i> , 2011, 13, 49-69.	1.3	35
107	Immunosuppressants Pharmacogenomics. , 2011, , 249-265.		0
108	Pharmacogenomic Testing in Current Clinical Practice. , 2011, , .		2
109	Conversion to Low-Dose Tacrolimus or Rapamycin 3 Months After Kidney Transplantation: A Prospective, Protocol Biopsy-Guided Study. <i>Transplantation Proceedings</i> , 2011, 43, 519-523.	0.3	16
110	Comparison of Basiliximab and Daclizumab With Triple Immunosuppression in Renal Transplantation. <i>Transplantation Proceedings</i> , 2011, 43, 453-457.	0.3	13
111	Screening of mortality in transplant patients using an assay for immune function. <i>Transplant Immunology</i> , 2011, 24, 246-250.	0.6	23
112	The clinical value of enzyme-multiplied immunoassay technique monitoring the plasma concentrations of cyclosporine A after renal transplantation. <i>Journal of Pharmaceutical Analysis</i> , 2011, 1, 139-142.	2.4	0
113	Long-term outcome of everolimus treatment in transplant patients. <i>Transplant Research and Risk Management</i> , 2011, , 77.	0.7	9
114	Manejo da doena crnica do enxerto renal. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2011, 33, 485-492.	0.4	5
115	Chronic Allograft Nephropathy. , 0, , .		1
116	Efficacy of Cordyceps sinensis in long term treatment of renal transplant patients. <i>Frontiers in Bioscience - Elite</i> , 2011, E3, 301-307.	0.9	17
117	Calcineurin inhibitors in kidney transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , 2011, 20, 610-615.	1.0	45

#	ARTICLE	IF	CITATIONS
118	Gastrointestinal Quality of Life Improvement of Renal Transplant Recipients Converted From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Drugs or Agents: Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium. <i>Transplantation</i> , 2011, 92, 426-432.	0.5	48
119	Everolimus and Long-Term Outcomes in Renal Transplantation. <i>Transplantation</i> , 2011, 92, S3-S26.	0.5	22
120	Early and delayed effects of AST-120 on chronic cyclosporine nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1502-1515.	0.4	10
121	Immunosuppression and renal transplant rejection: review of current and emerging therapies. <i>Clinical Investigation</i> , 2011, 1, 859-877.	0.0	3
122	Chronic Progressive Calcineurin Nephrotoxicity: An Overstated Concept. <i>American Journal of Transplantation</i> , 2011, 11, 687-692.	2.6	55
123	Sotrostauroin, a Novel Small Molecule Inhibiting Protein-Kinase C: Randomized Phase II Study in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2011, 11, 1444-1455.	2.6	75
124	Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF—Four-Year Results of the Postconcept Study. <i>American Journal of Transplantation</i> , 2011, 11, 1665-1675.	2.6	84
125	The PROMISE Study: A Phase 2b Multicenter Study of Voclosporin (ISA247) Versus Tacrolimus in De Novo Kidney Transplantation. <i>American Journal of Transplantation</i> , 2011, 11, 2675-2684.	2.6	79
126	Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. <i>Transplantation Reviews</i> , 2011, 25, 58-64.	1.2	65
127	Our evolving understanding of late kidney allograft failure. <i>Current Opinion in Organ Transplantation</i> , 2011, 16, 594-599.	0.8	17
128	Adjuvant Radiotherapy for a Prostate Cancer After Renal Transplantation and Review of the Literature. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 1282-1286.	0.6	13
129	Metabolic Syndrome in Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1781-1785.	2.2	58
130	Meta-Analysis of Calcineurin-Inhibitor-Sparing Regimens in Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 2107-2118.	3.0	127
131	Immunosuppression: Does One Regimen Fit All?. <i>Transplantation</i> , 2011, 92, 251-261.	0.5	27
132	An evaluation of sirolimus in renal transplantation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 1337-1356.	1.5	26
133	Using Donor-Specific Antibodies to Monitor the Need for Immunosuppression. <i>Transplantation</i> , 2012, 93, 1173-1178.	0.5	32
134	Randomized Trial Comparing Late Concentration-Controlled Calcineurin Inhibitor or Mycophenolate Mofetil Withdrawal. <i>Transplantation</i> , 2012, 93, 887-894.	0.5	32
135	Late Calcineurin Inhibitor Withdrawal Prevents Progressive Left Ventricular Diastolic Dysfunction in Renal Transplant Recipients. <i>Transplantation</i> , 2012, 94, 721-728.	0.5	12



#	ARTICLE	IF	CITATIONS
137	Using Historical Data With Bayesian Methods in Early Clinical Trial Monitoring. <i>Statistics in Biopharmaceutical Research</i> , 2012, 4, 384-394.	0.6	8
138	Belatacept: a new biological agent for maintenance immunosuppression in kidney transplantation. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 965-979.	1.4	20
139	Current trends in immunosuppressive therapies for renal transplant recipients. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 1961-1975.	0.5	51
140	Future Trends in Organ Transplant Recipients – Important Issues for Dermatologists. <i>Current Problems in Dermatology</i> , 2012, 43, 71-80.	0.8	3
141	Induction Therapy in Renal Transplant Recipients. <i>Drugs</i> , 2012, 72, 671-683.	4.9	31
142	The over-exaggerated chronic nephrotoxicity of calcineurin inhibitors. <i>Arab Journal of Urology Arab Association of Urology</i> , 2012, 10, 169-174.	0.7	4
143	Analytical Validation of a Homogeneous Immunoassay for Determination of Mycophenolic Acid in Human Plasma. <i>Transplantation Proceedings</i> , 2012, 44, 2669-2672.	0.3	9
144	Cyclosporine: A Review. <i>Journal of Transplantation</i> , 2012, 2012, 1-7.	0.3	196
145	Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation. <i>Journal of Transplantation</i> , 2012, 2012, 1-7.	0.3	9
146	Individualized immunosuppression in transplant patients: potential role of pharmacogenetics. <i>Pharmacogenomics and Personalized Medicine</i> , 2012, 5, 63.	0.4	11
147	Machine perfusion following static cold storage preservation in kidney transplantation: donor-matched pair analysis of the prognostic impact of longer pump time. <i>Transplant International</i> , 2012, 25, 34-40.	0.8	20
148	Challenges and considerations in diagnosing the kidney disease in deteriorating graft function. <i>Transplant International</i> , 2012, 25, 1119-1128.	0.8	13
149	Calcineurin Inhibitor Nephrotoxicity: A Review and Perspective of the Evidence. <i>American Journal of Nephrology</i> , 2013, 37, 602-612.	1.4	181
150	Kidney Transplant Outcomes. , 2013, , 459-467.		0
151	Current pharmacotherapeutical options for the prevention of kidney transplant rejection. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1029-1041.	0.9	2
152	Monitoring of Pathogen-Specific T-Cell Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2013, 4, 276.	2.2	13
153	Symptomatic lymphocele developing soon after acute renal allograft rejection: coincidental or causal connection?. <i>CKJ: Clinical Kidney Journal</i> , 2013, 6, 643-645.	1.4	0
154	The role of belataceptin transplantation: results and implications of clinical trials in the context of other new biological immunosuppressant agents. <i>Clinical Transplantation</i> , 2013, 27, E3-11.	0.8	4

#	ARTICLE	IF	CITATIONS
155	Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients. <i>Clinical Transplantation</i> , 2013, 27, 16-29.	0.8	13
156	Impact of Late Calcineurin Inhibitor Withdrawal on Ambulatory Blood Pressure and Carotid Intima Media Thickness in Renal Transplant Recipients. <i>Transplantation</i> , 2013, 96, 49-57.	0.5	19
157	A Randomized, Open-Label Study of Sirolimus Versus Cyclosporine in Primary De Novo Renal Allograft Recipients. <i>Transplantation</i> , 2013, 95, 1233-1241.	0.5	38
158	Reduced-dose Cyclosporine with Mycophenolate Mofetil and Prednisone Significantly Improves the Long-term Glomerular Filtration Rate and Graft Survival. <i>Internal Medicine</i> , 2013, 52, 947-953.	0.3	2
159	Tacrolimus Inhibits NF- $\kappa$ B Activation in Peripheral Human T Cells. <i>PLoS ONE</i> , 2013, 8, e60784.	1.1	57
161	ELEVATE: an innovative study design to assess the efficacy, safety, and evolution of cardiovascular parameters in de novo kidney transplant recipients after early conversion from a calcineurin inhibitor to everolimus. <i>Open Access Journal of Clinical Trials</i> , 2014, , 17.	1.5	2
162	Next-generation calcineurin inhibitors in development for the prevention of organ rejection. <i>Transplant Research and Risk Management</i> , 0, , 23.	0.7	0
163	Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients. <i>Journal of Translational Medicine</i> , 2014, 12, 331.	1.8	41
164	Risk of serious opportunistic infections after solid organ transplantation: interleukin-2 receptor antagonists versus polyclonal antibodies. A meta-analysis. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 881-896.	2.0	6
165	Treatment-Resistant Hypertension in the Transplant Recipient. <i>Seminars in Nephrology</i> , 2014, 34, 560-570.	0.6	13
166	A single-centre, open-label, prospective study of an initially short-term intensified dosing regimen of enteric-coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live-donor kidney transplant recipients. <i>International Journal of Clinical Practice</i> , 2014, 68, 23-30.	0.8	6
167	A Systematic Review of Conversion From Calcineurin Inhibitor to Mammalian Target of Rapamycin Inhibitors for Maintenance Immunosuppression in Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2014, 14, 2106-2119.	2.6	123
170	Transplantation: Kidney, Kidney-Pancreas Transplant. , 2014, , 175-201.		0
172	Immunosuppression in Transplantation. , 2014, , 564-574.		0
173	Exposure to Mycophenolic Acid Better Predicts Immunosuppressive Efficacy Than Exposure to Calcineurin Inhibitors in Renal Transplant Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 508-515.	2.3	34
174	Calcineurin Inhibitor Avoidance and Withdrawal for Kidney Transplantation: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Transplantation Proceedings</i> , 2014, 46, 1302-1313.	0.3	14
175	Immune Minimization Strategies in Renal Transplantation. <i>Immunological Investigations</i> , 2014, 43, 807-818.	1.0	3
176	Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation. <i>World Journal of Gastroenterology</i> , 2014, 20, 11356.	1.4	12

#	ARTICLE	IF	CITATIONS
177	A Prospective Randomised Paired Trial of Sirolimus versus Tacrolimus as Primary Immunosuppression following Non-Heart Beating Donor Kidney Transplantation. <i>Current Urology</i> , 2014, 7, 174-180.	0.4	8
179	Immunological risks of minimization strategies. <i>Transplant International</i> , 2015, 28, 901-910.	0.8	12
180	Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation. <i>Transplant International</i> , 2015, 28, 928-937.	0.8	11
181	Cyclosporine Therapy for Kidney Transplant: What is New for an Old-Fashioned Therapy?. , 2015, 05, .		2
182	Advances in pharmacotherapy to treat kidney transplant rejection. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1627-1648.	0.9	9
183	Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 3114-3122.	3.0	172
184	What immunosuppression should be used for old-to-old recipients?. <i>Transplantation Reviews</i> , 2015, 29, 231-236.	1.2	16
185	Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 64-72.	1.0	2
186	Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis. <i>American Journal of Transplantation</i> , 2016, 16, 2117-2138.	2.6	83
187	The epoxyeicosatrienoic acid analog PVPA ameliorates cyclosporine-induced hypertension and renal injury in rats. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, F576-F585.	1.3	17
189	Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study. <i>Transplant International</i> , 2016, 29, 1226-1236.	0.8	50
190	Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2016, 16, 3255-3261.	2.6	71
191	The efficacy and safety of intensified enteric-coated mycophenolate sodium with low exposure of calcineurin inhibitors in Chinese de novo kidney transplant recipients: a prospective study. <i>International Journal of Clinical Practice</i> , 2016, 70, 22-30.	0.8	6
192	Early subclinical rejection treated with low dose i.v. steroids is not associated to graft survival impairment: 13-years' experience at a single center. <i>Journal of Nephrology</i> , 2016, 29, 443-449.	0.9	8
193	Higher calcineurin inhibitor levels predict better kidney graft survival in patients with de novo donor-specific anti-HLA antibodies: a cohort study. <i>Transplant International</i> , 2017, 30, 502-509.	0.8	21
195	Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients. <i>The Cochrane Library</i> , 2017, 2017, CD006750.	1.5	45
196	Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data. <i>American Journal of Transplantation</i> , 2017, 17, 1358-1369.	2.6	67
197	Hypertension in Patients with Cardiac Transplantation. <i>Medical Clinics of North America</i> , 2017, 101, 53-64.	1.1	17

#	ARTICLE	IF	CITATIONS
198	Immunosuppression for kidney transplantation: Where are we now and where are we going?. <i>Transplantation Reviews</i> , 2017, 31, 10-17.	1.2	107
199	Early Conversion to Prednisolone/Everolimus as an Alternative Weaning Regimen Associates With Beneficial Renal Transplant Histology and Function: The Randomized-Controlled MECANO Trial. <i>American Journal of Transplantation</i> , 2017, 17, 1020-1030.	2.6	29
200	Cyclosporine Sparing Effect of Enteric-Coated Mycophenolate Sodium in De Novo Kidney Transplantation. <i>Yonsei Medical Journal</i> , 2017, 58, 217.	0.9	2
201	Induction Immunosuppression in Kidney Transplantation. , 2017, , 247-258.		0
202	Maintenance Immunosuppression in Kidney Transplantation. , 2017, , 259-276.		0
203	Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial. <i>Transplantation Direct</i> , 2018, 4, e380.	0.8	19
204	Tacrolimus prevents von Willebrand factor secretion by allostimulated human glomerular endothelium. <i>American Journal of Transplantation</i> , 2018, 18, 2314-2321.	2.6	7
205	Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 1359.	2.2	58
206	Azathioprine and Mycophenolates. , 2019, , 212-230.		1
207	Effects of late cyclosporine withdrawal on renal graft function and survival. <i>Journal of Nephrology</i> , 2019, 32, 315-321.	0.9	0
208	Immunosuppressive Therapy. , 2019, , 591-604.e3.		1
209	Epidemiology of end-stage renal failure among twins and diagnosis, management, and current outcomes of kidney transplantation between identical twins. <i>American Journal of Transplantation</i> , 2020, 20, 761-768.	2.6	2
210	Rethinking clinical endpoints in kidney transplant trials. <i>Current Opinion in Organ Transplantation</i> , 2020, 25, 1-7.	0.8	12
211	Clinical Study of Standard- vs Reduced-Dose Tacrolimus Combined With Generic Mycophenolate Mofetil in De Novo Kidney Transplantation: A Prospective Randomized Trial. <i>Transplantation Proceedings</i> , 2020, 52, 133-139.	0.3	0
212	Can Mammalian Target of Rapamycin Inhibitors Replace Mycophenolate in Hypersensitized Kidney Transplant Recipients?. <i>Transplantation</i> , 2020, 104, 1535-1536.	0.5	0
213	Proteomic Characterization of Urinary Extracellular Vesicles from Kidney-Transplanted Patients Treated with Calcineurin Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7569.	1.8	12
214	Challenges of calcineurin inhibitor withdrawal following combined pancreas and kidney transplantation: Results of a prospective, randomized clinical trial. <i>American Journal of Transplantation</i> , 2020, 20, 1668-1678.	2.6	15
215	Outcomes of Interleukin-2 Receptor Antagonist Induction Therapy in Standard-Risk Renal Transplant Recipients Maintained on Tacrolimus: A Systematic Review and Meta-Analysis. <i>American Journal of Nephrology</i> , 2021, 52, 279-291.	1.4	7

#	ARTICLE	IF	CITATIONS
216	Induction therapy with mesenchymal stromal cells in kidney transplantation: a meta-analysis. <i>Stem Cell Research and Therapy</i> , 2021, 12, 158.	2.4	4
217	Impact of Subclinical and Clinical Kidney Allograft Rejection Within 1 Year Posttransplantation Among Compatible Transplant With Steroid Withdrawal Protocol. <i>Transplantation Direct</i> , 2021, 7, e706.	0.8	0
218	Chronic Kidney Allograft Disease: New Concepts and Opportunities. <i>Frontiers in Medicine</i> , 2021, 8, 660334.	1.2	5
219	Long-Term Survival after Kidney Transplantation. <i>New England Journal of Medicine</i> , 2021, 385, 729-743.	13.9	239
220	Kidney Disease. , 2012, , 1523-1607.		5
221	Clinical Management. , 2012, , 2515-2555.		3
222	Reduced Tacrolimus Trough Level Is Reflected by Estimated Glomerular Filtration Rate (eGFR) Changes in Stable Renal Transplantation Recipients: Results of the OPTIMUM Phase 3 Randomized Controlled Study. <i>Annals of Transplantation</i> , 2018, 23, 401-411.	0.5	4
223	The Administration of Crizotinib to a ROS1-positive Advanced Non-small Cell Lung Carcinoma Patient Under Immunosuppressive Therapy After Renal Transplantation: a Case Report. <i>Japanese Journal of Lung Cancer</i> , 2020, 60, 197-201.	0.0	1
224	Cyclosporine-Associated Nephrotoxicity. <i>Open Journal of Nephrology</i> , 2013, 03, 168-180.	0.0	9
225	Modern Immunosuppressive Therapy in Kidney Transplantation. <i>Open Journal of Organ Transplant Surgery</i> , 2013, 03, 22-31.	0.3	8
226	Lymphocele after renal transplantation, a medical complication. <i>Journal of Nephrology</i> , 2011, 24, 707-716.	0.9	23
227	Glomerular filtration rate: utility for assessing long-term renal allograft outcomes in kidney allograft recipients. <i>Journal of Nephrology</i> , 2013, 26, 1009-1024.	0.9	8
228	Hypertension: The Neglected Complication of Transplantation. <i>ISRN Hypertension</i> , 2013, 2013, 1-10.	0.2	10
229	Is it time to give up with calcineurin inhibitors in kidney transplantation?. <i>World Journal of Transplantation</i> , 2013, 3, 7.	0.6	35
230	Calcineurin inhibitor sparing immunosuppressive regimens in kidney allograft recipients. <i>Polish Archives of Internal Medicine</i> , 2009, 119, 318-325.	0.3	2
231	Optimizing Immunosuppression. , 2010, , 137-152.		0
232	Immunosuppressive Therapy in Kidney and Pancreas Transplantation. , 2011, , 49-86.		0
233	Current Immunosuppression in Abdominal Organ Transplantation. , 0, , .		1

#	ARTICLE	IF	CITATIONS
235	Hypertension in the Kidney Transplant Recipient. , 2014, , 205-224.		0
236	Mycophenolates. , 2014, , 250-266.		0
237	Drug-Induced Seizures in Critically Ill Patients. , 2017, , 321-341.		1
238	Hypertension in cardiac transplant recipients. Vestnik Transplantologii I Iskusstvennykh Organov, 2017, 19, 114-125.	0.1	1
239	Calcineurin inhibitors and arterial hypertension in recipients of solid organs. Systemic Hypertension, 2017, 14, 84-86.	0.1	0
240	History of organ transplantation and the development of key immunosuppressants. Journal of the Korean Medical Association, 2020, 63, 241-250.	0.1	2
241	Immunological Detection Methods for Biomarkers. RSC Detection Science, 2020, , 223-252.	0.0	0
242	The blockade of T-cell co-stimulation as a therapeutic stratagem for immunosuppression: Focus on belatacept. Biologics: Targets and Therapy, 2007, 1, 203-13.	3.0	10
243	Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation. Biologics: Targets and Therapy, 2009, 3, 319-36.	3.0	13
244	Chronic Rejection and Atherosclerosis in Post-Transplant Cardiovascular Mortality: Two Sides of the Same Coin. Heart Lung and Circulation, 2021, , .	0.2	2
245	Is the failure of recent trials on withdrawal of calcineurin inhibitors due to inadequate mycophenolic acid dosing?. Journal of Nephrology, 2022, , 1.	0.9	0
246	Personalized immunosuppression after kidney transplantation. Nephrology, 2022, , .	0.7	9
253	Anti-interleukin-2 receptor antibodies&mdash;basiliximab and daclizumab&mdash;for the prevention of acute rejection in renal transplantation. Biologics: Targets and Therapy, 2009, 3, 319.	3.0	7
254	Hypertension in kidney transplant recipients. World Journal of Transplantation, 2022, 12, 211-222.	0.6	7
255	Kidney Disease after Heart and Lung Transplantation. Methodist DeBakey Cardiovascular Journal, 2022, 18, 34-40.	0.5	1
256	Immunosuppression in Transplantation. , 2018, , 589-600.e2.		0